AdBio opens Montréal office with €120M Fund III, backed by FTQ

The move, first reported by BetaKit, marks a cross-border push by a European life-sciences specialist into Canada’s startup hub.

AdBio’s arrival comes amid recent funding activity in Montréal, including Scopia’s $2.65-million pre-seed and Onix’s $5-million pre-seed for its AI platform. The firm’s expansion may reflect broader trends, such as investor appetite for markets where valuations could be more favorable. The FTQ’s backing could indicate a willingness among Québec’s institutional investors to explore partnerships with international firms.

The timing aligns with a busy period for Montréal’s startup scene, including Axya’s $17-million Series A and xSeek’s acquisition of LLMonade. However, these deals have largely involved domestic capital, with few international players participating. AdBio’s Fund III might offer new opportunities, particularly if it seeks companies that have exhausted local funding options. The firm’s experience in Europe could appeal to founders navigating regulatory and scaling challenges.

Still, details remain unclear. AdBio’s press release did not specify how much of the €120 million might be allocated to Canadian deals or whether the firm intends to lead investments. Montréal’s life-sciences ecosystem, while active, has not yet seen a company achieve global prominence. AdBio’s success may depend on its ability to identify promising targets, though it remains to be seen whether Canadian startups can deliver on such expectations.

For now, the office opening reflects optimism about Montréal’s potential. If AdBio secures deals, it could encourage other European VCs to explore Canada. If not, the €120 million may serve as a reminder of the challenges in bridging international investment with local opportunities.

Sources: betakit.com